In 1584 adults with CKD and albuminuria but no diabetes, finerenone slowed annual eGFR decline vs placebo over 32 months (−3.3 vs −4.0 ml/min/1.73 m²; difference 0.7). Secondary kidney or CV composite HR 0.77. Hyperkalaemia 17.0% vs 13.3%.
RCTn = 1,584
Heerspink et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes